CA2373879A1 - Therapie antivirale - Google Patents

Therapie antivirale Download PDF

Info

Publication number
CA2373879A1
CA2373879A1 CA002373879A CA2373879A CA2373879A1 CA 2373879 A1 CA2373879 A1 CA 2373879A1 CA 002373879 A CA002373879 A CA 002373879A CA 2373879 A CA2373879 A CA 2373879A CA 2373879 A1 CA2373879 A1 CA 2373879A1
Authority
CA
Canada
Prior art keywords
hiv
viral
treatment
pharmaceutical composition
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373879A
Other languages
English (en)
Inventor
Johannes Servatius Leonardus Maria Nottet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rijksuniversiteit Utrecht
Utrecht Universitair Medisch Centrum
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202156A external-priority patent/EP1064940A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2373879A1 publication Critical patent/CA2373879A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

l'invention relève du domaine des agents antiviraux et plus particulièrement de la thérapie antivirale. L'invention concerne l'utilisation d'au moins un composé ou d'un mélange de composés correspondant à la formule générale (I) ou encore d'un équivalent fonctionnel ou d'un sel ou d'un hydrate pharmaceutiquement acceptable de celui-ci, qui vise la production d'une composition pharmaceutique destinée au traitement d'une infection virale.
CA002373879A 1999-07-02 2000-06-30 Therapie antivirale Abandoned CA2373879A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14229799P 1999-07-02 1999-07-02
US60/142,297 1999-07-02
EP99202156.8 1999-07-02
EP99202156A EP1064940A1 (fr) 1999-07-02 1999-07-02 Thérapie antivirale
EP00200991 2000-03-17
EP00200991.8 2000-03-17
PCT/NL2000/000460 WO2001001985A1 (fr) 1999-07-02 2000-06-30 Therapie antivirale

Publications (1)

Publication Number Publication Date
CA2373879A1 true CA2373879A1 (fr) 2001-01-11

Family

ID=56290036

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373879A Abandoned CA2373879A1 (fr) 1999-07-02 2000-06-30 Therapie antivirale

Country Status (7)

Country Link
EP (1) EP1194141B1 (fr)
JP (1) JP2003503455A (fr)
AT (1) ATE301997T1 (fr)
AU (1) AU5856100A (fr)
CA (1) CA2373879A1 (fr)
DE (1) DE60022047T2 (fr)
WO (1) WO2001001985A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
EP1452605A1 (fr) * 2003-02-27 2004-09-01 Universiteit Utrecht Holding B.V. Procédé de détermination d'activité antivirale
EP3510172B1 (fr) * 2016-09-07 2023-11-29 St Vincent's Hospital Sydney Limited Méthodes de détection du vih

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028292A1 (fr) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Nouveaux composes renfermant de la piperidine
US5973191A (en) * 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
CA2313049A1 (fr) * 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. . inhibition de la cyclooxygenase-2

Also Published As

Publication number Publication date
ATE301997T1 (de) 2005-09-15
DE60022047T2 (de) 2006-06-29
WO2001001985A1 (fr) 2001-01-11
EP1194141A1 (fr) 2002-04-10
DE60022047D1 (de) 2005-09-22
JP2003503455A (ja) 2003-01-28
EP1194141B1 (fr) 2005-08-17
AU5856100A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
Rice et al. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins
CN104136081B (zh) 再活化潜伏hiv病毒的巨大戟二萜醇衍生物
US20080038716A1 (en) Cell lines with latent immunodeficiency virus and methods of use thereof
Hartman et al. The Continuing Evolution of HIV‐1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets
WO2008088806A1 (fr) Paradigme combinatoire combattant les infections vih, vih/hsv ou vih/hpv chez l'être humain au moyen de composés végétaux de faible masse moléculaire
KR20020024587A (ko) 염증 매개성 감염에 대한 항염증 치료
US6787573B2 (en) Antiviral therapy
WO2010099169A2 (fr) Nouveau modèle in vitro de latence du vih-1 pour le criblage d'agents de réactivation du vih-1
Baba Cellular factors as alternative targets for inhibition of HIV-1
EP1194141B1 (fr) Therapie antivirale
US20160015759A1 (en) Compositions and methods for treating an immunodeficiency virus infection
US6387959B1 (en) Antiviral therapy
EP1263429B1 (fr) Therapie antivirale
EP1064940A1 (fr) Thérapie antivirale
US20110305662A1 (en) Methods of treating immunodeficiency virus infection
JUNKER et al. Antiviral Potency of Drug—Gene Therapy Combinations against Human Immunodeficiency Virus Type 1
Mannioui et al. Cell cycle regulation of human immunodeficiency virus type 1 integration in T cells: antagonistic effects of nuclear envelope breakdown and chromatin condensation
Richard Documentation and molecular analysis of African medicinal plants and naturally-produced chemical compounds that modulate latent HIV-1 infection
EP1452605A1 (fr) Procédé de détermination d'activité antivirale
WO1997034593A1 (fr) AGONISTES UTILES DANS LA COSTIMULATION DE LYMPHOCYTES T INDUITS PAR TcR/CD3
JP2021187761A (ja) 抗ＳＡＲＳ−ＣｏＶ−２薬
Warachit et al. Aberrant life cycle of human immunodeficiency virus type 1 CRF15_01B-like clinical isolates from Thailand in human CD4+ T-cell lines
Yang Dehydroepiandrosterone (DHEA) as a potential anti-human immunodeficiency virus type one agent to investigate the pathogenesis of HIV-1
Laird TARGETING THE HIV-1 LATENT RESERVOIR FOR ERADICATION USING SMALL MOLECULES
HealthCare Reinhold Welker Bayer HealthCare, Wuppertal, Germany Helga Rübsamen-Waigmann Bayer HealthCare, Wuppertal, and University of Frankfurt, Frankfurt, Germany

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued